Absci Appoints Biopharma Leader Mary Szela to Board of Directors

Core Insights - Absci has appointed Mary Szela, a veteran biopharmaceutical executive, to its Board of Directors, bringing over three decades of commercial and clinical leadership experience [1][2] - Szela's expertise includes the global launch and expansion of Humira, a highly successful therapy, and she has held significant roles in various biopharmaceutical companies [2][3] - Absci is focused on accelerating the development of its AI-designed therapeutics, including ABS-101 for inflammatory bowel disease and ABS-201 for androgenetic alopecia [3][4] Company Overview - Absci is a clinical-stage biopharmaceutical company utilizing generative AI to create innovative biologics, aiming to enhance drug discovery and development processes [4] - The company's Integrated Drug Creation™ platform combines advanced AI models with synthetic biology, facilitating rapid design and validation of therapeutics [4] - Absci's pipeline includes ABS-101, an anti-TL1A antibody for inflammatory bowel disease, and ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia, with clinical developments expected in the near future [3][4]